权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cell-Selective Therapies for Coronary Artery Disease

冠状动脉疾病的细胞选择性疗法

基本信息

批准号：
10543849
负责人：
Hana Totary-Jain
金额：
$ 48.6万
依托单位：
UNIVERSITY OF SOUTH FLORIDA
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-15 至 2025-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10543849
关键词：
Adenovirus Vector Affect Animal Model Apolipoprotein E Arterial Fatty Streak Atherosclerosis Biological Blood Vessels Cannulations Cardiovascular Diseases Cardiovascular system Carotid Arteries Categories Cause of Death Cell physiology Cells Cessation of life Clinical Clinical Research Coronary Arteriosclerosis Coronary artery Cyclin-Dependent Kinase Inhibitor Development Endothelial Cells Endothelium Epidemic Event Exhibits Foundations Functional disorder Goals Heart Human Hyperplasia Incidence Infection Inflammation Inflammatory Infiltrate Injury Interleukin-1 beta Intervention Knock-out Lipids Messenger RNA MicroRNAs Modeling Mus Oryctolagus cuniculus Penetration Peptides Pharmaceutical Preparations Physiology Proteins Rattus Recurrence Regional Perfusion Resistance Safety Site Small Interfering RNA Smooth Muscle Myocytes Technology Testing Therapeutic Thrombophilia Thrombosis Time Toxic effect Translating Untranslated Regions Vascular Endothelial Cell Vascular Smooth Muscle Venous cyclin-dependent kinase inhibitor 1B design disability efficacy evaluation endonuclease ex vivo perfusion femoral artery healing human tissue mouse model nanoparticle nanoswitch nanotherapeutic nanotherapy novel novel strategies overexpression personalized medicine pharmacologic preclinical study protein expression recombinant virus response restenosis self assembly tool translational potential treatment strategy uptake vascular smooth muscle cell proliferation

项目摘要

Atherosclerotic cardiovascular disease (CVD) represents a serious affliction affecting millions globally. Despite recent advances in pharmacological and percutaneous interventions, CVD remains the leading cause of death and disability in the world. One of the main therapeutic challenges facing atherosclerotic CVD is the delivery of therapies to the atherosclerotic plaque that target the specific cells which contribute to its formation, while protecting the endothelium. Vascular endothelial cells provide crucial protection against lipid uptake, inflammation and thrombosis. We hypothesize that cell-selective therapy that inhibits infiltration of inflammatory cells and proliferation of vascular smooth muscle cells, while protecting endothelia cell function will be effective in combating CVD and thrombosis. To achieve this goal, we will develop a novel miRNA switch that combines synthetically modified mRNA with miRNA target site. As a delivery platform we will utilize the cationic amphipathic cell-penetrating peptide that forms a self-assembled, compacted, nanoparticle when mixed with synthetic mRNA. Moreover, to increase the targeting of inflammation in the atherosclerotic plaque, we will combine the miRNA switch together with siRNA targeting IL1-β to generate nanoparticles using the same cationic amphipathic cell- penetrating peptide. In two specific aims, we will test 1) the efficacy of this cell-selective nanotherapy to inhibit atherosclerosis and restenosis after percutaneous intervention, while protecting EC to reduce thrombosis; and 2) the translational potential of the miRNA switch nanotherapy in viable, isolated human coronary arteries. Completion of the aims will provide the foundation for the development of a novel category of biological drugs that can accommodate the advent of personalized medicine and will advance the treatment of cardiovascular disease.

动脉粥样硬化性心血管疾病（CVD）是影响全球数百万人的严重疾病。尽管